Literature DB >> 2014254

Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.

C J Gibbs1, R Peters, M Gravell, B K Johnson, F C Jensen, D J Carlo, J Salk.   

Abstract

Two human immunodeficiency virus (HIV)-seropositive chimpanzees (A-3 and A-86c) infected 4 yr earlier with HIV, along with one uninfected animal (A-36), were inoculated intramuscularly three times in a year with a gamma-irradiated gp120-depleted HIV immunogen in incomplete Freund's adjuvant. Both previously infected animals promptly developed an anamnestic humoral antibody response after the first dose, and the uninfected animal developed a primary humoral response to the first dose and then an anamnestic response to the second dose. Although HIV had been recovered repeatedly from the seropositive animals, they became persistently virus-culture negative at the time of or just before the first inoculation of the immunogen. Intravenous challenge with 40 chimpanzee-infectious-doses of a heterologous HIV strain (HIVIIIB) was done 4 mo after the third inoculation in the three treated chimpanzees and in an untreated control animal (A-189a). The immunized naive animal (A-36) and the unimmunized control (A-189a) became infected, and virus has been isolated from their peripheral blood mononuclear cells for greater than 2 yr after challenge. However, the two previously infected chimpanzees (A-3 and A-86c) resisted challenge and have remained virus negative by peripheral blood mononuclear cell cocultivation for greater than 2 yr of observation after challenge; moreover, no evidence of reinfection was detectable by PCR. Despite the in vivo resistance, however, peripheral blood mononuclear cells from the resistant animals (A-3, A-86c) remained susceptible to infection by HIV in vitro. These findings reveal that a state of immunity can develop and/or be induced to control and/or prevent HIV infection in the chimpanzees. In the absence of any detectable level of neutralizing antibody in A-3 and a low level in A-86c, the patterns of the responses to challenge seen in the four animals suggest that the cell-mediated immune mechanism must have played a significant role in the resistant chimpanzees both in control of their HIV infection and in their resistance to challenge.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014254      PMCID: PMC51444          DOI: 10.1073/pnas.88.8.3348

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  7 in total

1.  Prospects for the control of AIDS by immunizing seropositive individuals.

Authors:  J Salk
Journal:  Nature       Date:  1987 Jun 11-17       Impact factor: 49.962

2.  Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa.

Authors:  J P Getchell; D R Hicks; A Svinivasan; J L Heath; D A York; M Malonga; D N Forthal; J M Mann; J B McCormick
Journal:  J Infect Dis       Date:  1987-11       Impact factor: 5.226

3.  The gag-specific cytotoxic T lymphocytes in rhesus monkeys infected with the simian immunodeficiency virus of macaques.

Authors:  M D Miller; C I Lord; V Stallard; G P Mazzara; N L Letvin
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

4.  Vaccine protection against simian immunodeficiency virus infection.

Authors:  R C Desrosiers; M S Wyand; T Kodama; D J Ringler; L O Arthur; P K Sehgal; N L Letvin; N W King; M D Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

5.  A formalin-inactivated whole SIV vaccine confers protection in macaques.

Authors:  M Murphey-Corb; L N Martin; B Davison-Fairburn; R C Montelaro; M Miller; M West; S Ohkawa; G B Baskin; J Y Zhang; S D Putney
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

Review 6.  An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.

Authors:  A C Allison; N E Byars
Journal:  J Immunol Methods       Date:  1986-12-24       Impact factor: 2.303

7.  Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins.

Authors:  A D Kitchen; G F Mann; J F Harrison; A J Zuckerman
Journal:  Vox Sang       Date:  1989       Impact factor: 2.144

  7 in total
  10 in total

1.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

3.  Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy.

Authors:  R B Moss; F Ferre; A Levine; J Turner; F C Jensen; A E Daigle; S P Richieri; A Truckenbrod; R J Trauger; D J Carlo; J Salk
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

4.  Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.

Authors:  R Shibata; C Siemon; M W Cho; L O Arthur; S M Nigida; T Matthews; L A Sawyer; A Schultz; K K Murthy; Z Israel; A Javadian; P Frost; R C Kennedy; H C Lane; M A Martin
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

Authors:  P Mooij; W M Bogers; H Oostermeijer; W Koornstra; P J Ten Haaft; B E Verstrepen; G Van Der Auwera; J L Heeney
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.

Authors:  B Rovinski; J R Haynes; S X Cao; O James; C Sia; S Zolla-Pazner; T J Matthews; M H Klein
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

7.  Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.

Authors:  D E Mosier; R J Gulizia; P D MacIsaac; L Corey; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

8.  Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats.

Authors:  W Song; E W Collisson; P M Billingsley; W C Brown
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

9.  Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.

Authors:  R Shibata; M D Hoggan; C Broscius; G Englund; T S Theodore; A Buckler-White; L O Arthur; Z Israel; A Schultz; H C Lane
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  OspA vaccination of mice with established Borrelia burgdorferi infection alters disease but not infection.

Authors:  E Fikrig; S W Barthold; R A Flavell
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.